

29 Apr 2024 | News

Quick Listen: Scrip's Five Must-Know Things

by [Ian Haydock](#)

In this week's podcast edition of Five Must-Know Things: 2023's top selling drugs and the COVID cliff; falling sales force Roche to reassess priorities; Phase III immunology win for Sanofi; BMS's strong pipeline: and which companies could be acquired next.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip's* global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 26 April 2024, including: 2023's top selling drugs and the COVID cliff; falling sales force [Roche Holding AG](#) to reassess priorities; Phase III immunology win for [Sanofi](#); [Bristol Myers Squibb Company](#)'s strong pipeline: and which companies could be acquired next.

This and all our other podcasts are available on the *Citeline* channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#), [TuneIn](#) and [Spotify Podcasts](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[Top-Selling Drugs 2023: Pharma's \\$60bn COVID-19 Cliff](#)" - Scrip, 24 Apr, 2024.)

(Also see "[Falling Sales Force New Priorities At Roche](#)" - Scrip, 24 Apr, 2024.)

(Also see "[Sanofi Clinches Key Phase III Immunology Win With Rilzabrutinib](#)" - Scrip, 23 Apr, 2024.)

(Also see "[BMS Has A Strong Pipeline, But Access Challenges Remain](#)" - Scrip, 23 Apr, 2024.)

(Also see "[Scrip M&A Podcast: Which Companies Could Be Acquired Next?](#)" - Scrip, 23 Apr, 2024.)

[Click here to explore this interactive content online](#) 